Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment

• DOI: 10.3389/fimmu.2021.751869
• Publication Date: 2021-12-23T16:41:40Z
• Authors: Nayoun Kim; Jong-Min Lee; Eun-Jee Oh; Dong Wook Jekarl; Dong-Gun Lee; Keon-Il Im; Seok-Goo Cho
• Keywords: ELISPOT; Adoptive Cell Transfer

Immunological characteristics of COVID-19 show pathological hyperinflammation associated with lymphopenia and dysfunctional T cell responses. These features provide a rationale for restoring functional immunity in patients by adoptive transfer SARS-CoV-2 specific cells.To generate cells, we isolated peripheral blood mononuclear cells from 7 recovered 13 unexposed donors. Consequently, stimulated peptide mixtures covering spike, membrane nucleocapsid proteins. Then, culture expanded IL-2 21 days. We assessed immunophenotypes, cytokine profiles, antigen specificity the final products.Our results that could be both groups. Immunophenotypes were similar groups showing CD4+ dominance, but CD8+ CD3+CD56+ also present. Antigen was determined ELISPOT, intracellular assay, cytotoxicity assays. One out 14 individuals who previously to failed specificity. Moreover, ex-vivo mainly consisted central effector memory subsets reduced alloreactivity against HLA-unmatched suggesting possibility development third-party partial HLA-matching products.In conclusion, our findings can readily therefore manufactured as biopharmaceutical product treat severe patients.Ex-vivo developed products may promising approach treating do not respond previous treatment options.